ReviewFrontiers in pharmacology2016
Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Therapy for squamous-cell carcinoma of the anus in HIV-positive patients.ESMO gastrointestinal oncology · 2026Review
- Body mass index and hemophagocytic lymphohistiocytosis: a risk assessment in HIV-positive leukemia patients.Annals of medicine and surgery (2012) · 2025Review
- HIV complicated with severe pulmonary adenocarcinoma: A case report.Experimental and therapeutic medicine · 2025Article
- Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co-Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer.Clinical pharmacology and therapeutics · 2023Article
- Virologic Nonsuppression Among Patients With HIV Newly Diagnosed With Cancer at Uganda Cancer Institute: A Cross-Sectional Study.JCO global oncology · 2023Article
- The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa.Breast cancer research and treatment · 2023Article
- Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity.Cancers · 2022Article
- Review
- Liver Transplantation for HCC in HIV-Infected Patients: Long-Term Single-Center Experience.Cancers · 2021Article
- Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.Archives of medical research · 2021Review
- Drug-Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PINPharmaceuticals (Basel, Switzerland) · 2021Article
- Non-Melanoma Skin Cancer in People Living With HIV: From Epidemiology to Clinical Management.Frontiers in oncology · 2021Review
- A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection.Breast cancer research and treatment · 2020Article
- Haemopoietic cell transplantation in patients living with HIV.The lancet. HIV · 2020Review
- Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.Critical reviews in oncology/hematology · 2020Review
- Inclusive Cancer Care: Rethinking Patients Living with HIV and Cancer.The oncologist · 2020Article
- Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment.International journal of molecular sciences · 2020Review
- Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era.JAMA oncology · 2020Observational
- Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study.Breast cancer research : BCR · 2019Observational
- Disparities and Determinants of Cancer Treatment in Elderly Americans Living With Human Immunodeficiency Virus/AIDS.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of Highly Active Antiretroviral Therapy (HAART) into clinical practice has dramatically changed the natural approach of HIV-related cancers. Several studies have shown that intensive antiblastic chemotherapy (AC) is feasible in HIV-infected patients with cancer, and that the outcome is similar to that of HIV-negative patients receiving the same AC regimens. However, the concomitant use of HAART and AC can result in drug accumulation or possible toxicity with consequent decreased efficacy of one or both classes of drugs. In fact, many AC agents are preferentially metabolized by CYP450 and drug-drug interactions (DDIs) with HAART are common. Therefore, it is important that HIV patients with cancer in HAART receiving AC treatment at the same time receive an individualized cancer management plan based on their liver and renal functions, their level of bone marrow suppression, their mitochondrial dysfunction, and their genotype profile. The rationale of this review is to summarize the existing data on the impact of HAART on the clinical management of cancer patients with HIV/AIDS and DDIs between antiretrovirals and AC. In addition, in order to maximize the efficacy of antiblastic therapy and minimize the risk of drug-drug interaction, a useful list of pharmacogenomic markers is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.